Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pyrotinib + capecitabine + bevacizumab
- Development stage
- Unknown
- Lead developer
- Jiangsu Hengrui Medicine
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of pyrotinib (an irreversible pan-ErbB receptor tyrosine kinase inhibitor), capecitabine (a chemotherapeutic agent), and bevacizumab (a monoclonal antibody targeting VEGF). This regimen is being investigated primarily for the treatment of HER2-positive breast cancer patients with brain metastases. The combination aims to target multiple pathways involved in tumor growth and progression: pyrotinib inhibits HER2 signaling, capecitabine provides cytotoxic effects, and bevacizumab prevents angiogenesis.
- Brand names
- AiRuiNiXelodaAvastin
- Other names
- SHR-1258SHR1258SHR 1258
02
Targets
ERBB4 (Erb-b2 receptor tyrosine kinase 4)TS (Thymidylate synthase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR (Epidermal growth factor receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on pyrotinib + capecitabine + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pyrotinib + capecitabine + bevacizumab.